Page 2532 - Williams Hematology ( PDFDrive )

2503
2502 Index Index 2503

for G6PD deficiency, 711 von Willebrand factor biosynthesis, von Willebrand factor (VWF) receptor,
normal levels, 652t 2166–2167, 2167f 1858–1859t
Vitamin E deficiency, 653 von Willebrand factor interaction with von Willebrand factor (VWF) replacement
Vitamin K factor VIII, 2168 therapy, 2176
neonate and, 109 von Willebrand factor role, 2167 Vorapaxar, 404t, 406, 2076–2077, 2295, 2297
for warfarin reversal, 396, 396t VWF and complementary DNA, 2164, Voriconazole
Vitamin K (menatetrenone), 1360 2166 as empiric therapy for infections, 385, 387t
2
Vitamin K antagonists, 393. See also Warfarin inheritance, 2171 prophylactic, 389
Vitamin K deficiency, 1986, 1986t, 1988, iron deficiency and, 629 Vorinostat, 336–337
1989f laboratory features, 1988, 2172–2174 for acute myelogenous leukemia, 1403
Vitamin K–dependent zymogens, 1915–1918, platelet-type (pseudo-), 2050–2051, 2165t, mechanism of action, 240
1916t, 1917f, 1918f, 1918t 2174 for mycosis fungoides, 1686–1687
factor VII. See Factor VII pregnancy and, 121 for myeloma, 1753t, 1754
factor IX. See Factor IX prenatal diagnosis, 2174 for primary effusion lymphoma, 1247
factor X. See Factor X terminology, 2164t Vosaroxin, for myelodysplastic syndromes,
protein C. See Protein C therapy, course, and prognosis, 1361
prothrombin. See Prothrombin (factor II) 2175–2176, 2318 VpreB, 1168
Vitamin K epoxide reductase complex type 1, 2165t, 2169–2170, 2171–2172, v-SNARE, 1010, 1018, 1849
(VKORC), 395 2175–2176 VTE. See Venous thrombosis/
Vitamins type 2A, 2165t, 2170, 2175–2176 thromboembolism
in erythrocytes, 470t type 2B, 2165t, 2170–2171, 2172, VWD. See Von Willebrand disease (VWD)
in neutrophils, 935 2175–2176 VWF. See Von Willebrand factor (VWF)
Vitronectin, 63–64, 1834, 1845, 1846t, 1865 type 2M, 2165t, 2171, 2175–2176 VWF, 1928, 2164, 2165f, 2168–2171, 2169f
Vitronectin receptor. See Integrin α β type 2N, 2165t, 2171, 2172, 2175–2176 VZV (varicella zoster virus) infections, 370,
v 3
VKORC (vitamin K epoxide reductase type 3, 1985, 2165t, 2170, 2172, 2175–2176 384
complex), 395 von Willebrand disease (VWD)-Normandy,
VLA (very-late-activation antigen), 1185, 2121 W
1712 von Willebrand factor (VWF) W515K/L, 1392
VLA-2. See Integrin α β binding to platelets, 2168 Waldenström hyperglobulinemic purpura,
2 1
VLA-4. See Integrin α β binding to vessel wall, 2167–2168 2099, 2099f
4 1
VLA-5. See Integrin α β biosynthesis, 2164, 2166–2167, 2167f Waldenström macroglobulinemia (WM),
5 1
VLA-6. See Integrin α β characteristics, 1916t, 1928 1785–1798
6 1
VODI (venoocclusive disease with collagen-binding activity, 2164t clinical features, 1788–1791, 1788t, 1789t
immunodeficiency), 1222 factor VIII and, 2164, 2168 autoantibody activity, 1789
Volasertib, for myelodysplastic syndromes, functions, 1928, 2167 cold agglutinin anemia, 827, 1790
1361 gene structure and variations, 1928 cryoglobulinemia, 1789, 1790f
Volume expanders, 2079 glycoprotein Ib and, 1866–1867 hyperviscosity syndrome, 428,
von Hippel-Lindau (VHL) protein-ubiquitin- in hepatic disease, 2191–2192 1788–1789, 1789f
proteasome pathway, 486, 486f history, 2163 immunoglobulin M tissue deposition,
von Hippel-Lindau (VHL) syndrome, classic, in inflammatory response, 1979 1790–1791
877–878 interactions, 1846t neuropathy, 1789–1790
von Willebrand disease (VWD), laboratory evaluation, 1988 platelet dysfunction, 2082
2163–2176 in liver transplantation, 2193 tissue infiltration by neoplastic cells,
acquired, 2082–2083, 2174–2175 penicillins and, 2078 1791
classification, 2165t in platelets, 1830–1831f, 1831, 1833–1834, course and prognosis, 1797–1798, 1797t
clinical features, 1987, 2171–2172 1845, 2164 definition and history, 1785
definition and history, 2163–2164 ristocetin binding to, 2168 differential diagnosis, 827
differential diagnosis, 2121, 2174–2175 structure, 1846t, 1928, 2254f epidemiology, 1785
epidemiology, 2171 terminology, 2164t etiology and pathogenesis, 1709–1710
etiology and pathogenesis, 2164–2171 in thrombotic thrombocytopenic purpura, gene mutations, 234t, 1712
molecular genetics, 2049f, 2168–2171, 2253–2254 laboratory features, 1786f, 1788t,
2168f, 2169f von Willebrand factor (VWF) antigen, 2164t, 1791–1792, 1792f
von Willebrand factor binding to 2173 pathogenesis
platelets, 2168 von Willebrand factor (VWF) multimers, 2173 B-cell clones, 1785–1786
von Willebrand factor binding to the von Willebrand factor (VWF) propeptide, gene mutations, 1786–1788, 1787f
vessel wall, 2167–2168 2166 marrow microenvironment, 1787f, 1788

Kaushansky_index_p2393-2506.indd 2503 9/21/15 3:23 PM